Sp. Range et al., Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle cells, EUR RESP J, 15(4), 2000, pp. 751-756
Cyclo-oxygenase (COX) inhibitors may have a role in reducing inflammation i
n asthma and other pulmonary diseases. COX inhibitors have different select
ivities for the two COX isoenzymes (COX 1 and COX 2) which vary between pur
ified enzyme and intact cell preparations. The relative selectivity of COX
inhibitors has not been studied in human airway cells,
A number of COX inhibitors in cultured human airway cells were compared whi
ch exclusively express either COX 1 (primary degree cultured human airway s
mooth muscle (HASM) cells) or COX 2 (A549 pulmonary epithelial cell-line) a
s measured by Western blotting.
COX activity was assayed by prostaglandin CPG)E-2 production following 30 m
in incubation with 5 mM arachidonic acid. COX activity in both cell types w
as similar; HASM cells 92.2+/-12.1 ng PGE(2).mg(-1) protein, A549 cells 87.
7+/-24.4 ng PGE(2).mg(-1) protein. In HASM cells the median inhibitory conc
entration (IC50) was >10(-5) M for nimesulide, 3.2 x 10(-6) M for N-(2-cycl
ohexyloxy-nitrophenyl)-methanesulphonamide (NS398), 1.8 x 10(-8) M for flur
biprofen, 6.7 x 10(-9) M for indomethacin and >10(-5) M for aspirin. In A54
9 cells the IC50 was 1.8 x 10(-9) M for nimesulide, 4.1 x 10(-9) M for NS39
8, 6.2 x 10(-10) M for flurbiprofen, 1.3 x 10(-8) M for indomethacin and >1
0(-5) M for aspirin. Sodium valerate had no effect in either HASM or A549 c
ells. The COX 2:COX 1 selectivity ratio (COX 2 IC50/COX 1 IC50) was <0.0001
for nimesulide, 0.001 for NS398, 0.03 for flurbiprofen and 1.9 for indomet
hacin,
In conclusion the present study has shown that cyclo-oxygenase inhibitors h
ave a range of selectivities for cyclo-oxygenase 1 and cyclo-oxygenase 2 in
intact human airway cells. The relative cyclo-oxygenase 2 selectivity of N
-(2-cyclohexyloxy-4-nitrophenyl)-methanesulphonamide and nimesulide may hav
e implications for the treatment of asthma and other inflammatory pulmonary
diseases.